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Cell Membrane Modification for Rapid Display of
Proteins as a Novel Means of Immunomodulation:
FasL-Decorated Cells Prevent Islet Graft Rejection
ates very slowly and in theory can be exploited to
achieve the display of proteins on the surface of cells
that have been modified with biotin. Nonetheless, for
this approach to serve as an alternative to gene transfer
schemes, it should allow for long-term display of pro-
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teins, and the process of biotinylation and decorationUniversity of Louisville
with exogenous proteins should not compromise theLouisville, Kentucky 40202
function of the cell nor those of the proteins to be dis-2 Center for Light Microscope Imaging
played.and Biotechnology
We tested this notion using a chimeric molecule (SA-Carnegie Mellon University
FasL) consisting of the biotin binding and tetramer-form-Pittsburgh, Pennsylvania 15213
ing domains of streptavidin and the extracellular portion
of FasL (Pahler et al., 1987; Suda et al., 1993). The choice
of FasL was due to its critical role in immune homeosta-Summary
sis and peripheral tolerance (Wu et al., 1994; Parijs et
al., 1996; Griffith et al., 1995). These aspects of FasLLong-term display of exogenous proteins on the cell
have been exploited for tolerance to transplantation andsurface may have important research and therapeutic
autoimmune antigens with conflicting results (Lau etimplications. We report a novel method for the cell-
al., 1996; Allison et al., 1997; Zhang et al., 1997, 1999).surface display of proteins that involves generation of
Ectopic expression of FasL in cells and tissues wasa chimeric protein with core streptavidin, biotinylation
shown to regulate auto- and alloimmune responses inof cells, and “decoration” with the protein. A chimeric
an antigen-specific manner (Lau et al., 1996; Zhang etprotein with the extracellular portions of FasL (SA-
al., 1997; Matsue et al., 1999). Cotransplantation of pan-FasL) was efficiently displayed on the cell surface
creatic islets with myoblasts genetically engineered towithin 2 hr without detectable cellular toxicity. Biotin
express FasL or with Sertoli cells with constitutive FasLand SA-FasL persisted on the cell surface for weeks
expression into allogeneic hosts resulted in the preven-in vitro and in vivo. Immunomodulation with SA-FasL-
tion of graft rejection (Lau et al., 1996; Takeda et al.,decorated splenocytes effectively blocked alloreac-
1998). In contrast, islets and hearts transgenically ex-tive responses in naive and presensitized rodents and
pressing FasL were rejected acutely by allogeneic hostsprevented the rejection of allogeneic pancreatic islets.
(Allison et al., 1997; Seino et al., 1998; Takeuchi et al.,This approach may serve as an alternative to gene
1999).transfer-based expression with broad research and
Although the source of these conflicting results istherapeutic applications.
presently unknown, the complex posttranslational regu-
lation of FasL and the different functions performed byIntroduction
the different forms of FasL may provide an explanation.
Although FasL is synthesized as a type II membraneIntroduction of recombinant genetic material into cells
protein, it is also secreted into the milieu as a solubleholds great potential for the treatment of a variety of
protein following cleavage by matrix metalloproteinaseshereditary and acquired diseases, including immune
(Tanaka et al., 1998; Bossi and Griffiths, 1999). FasL isdisorders (Bordignon et al., 1995; Anderson, 1998; Ca-
also synthesized and stored as a membrane-associated
vazzana-Calvo et al., 2000). Despite this great promise,
protein in microvesicles that are excreted into the milieu
there remain many barriers to the routine application
in selected cell types in response to various stimuli
of gene therapy in clinical practice. Major limitations (Bossi and Griffiths, 1999). These three different forms
include the uncertain safety and low efficiency of deliv- of FasL, membrane-bound, soluble, and vesicular, may
ery and expression vectors (Anderson, 1998). This raises differ in their function with respect to apoptosis and
the question whether selected goals of gene therapy immune regulation. Apoptosis is primarily mediated by
can be achieved by the delivery of exogenous proteins, the vesicular and membrane-bound forms of FasL,
rather than nucleic acids, to the cell. A variety of disor- whereas the soluble form is ineffective in mediating apo-
ders, particularly those of immune origin, may be treated ptosis and indeed serves as an antiapoptotic factor by
by transient display of proteins on the cell surface. competing for the Fas receptor with membrane-bound
Therefore, a method that would safely permit modifica- FasL (Suda et al., 1997; Schneider et al., 1998). Further-
tion of the cell membrane to achieve transient long- more, soluble FasL serves as a chemotactic factor for
term display of therapeutic proteins may have broad neutrophils, whereas membrane-bound and vesicular
applications in the clinic. To this end, we made use of forms lack this function (Seino et al., 1998; Ottonello
the high-affinity interaction (approximately Kd  1015 et al., 1999). In transplantation settings, where ectopic
M) of streptavidin with biotin (Pahler et al., 1987; Green, expression of FasL was demonstrated to have an injuri-
1990). Once formed, this noncovalent complex dissoci- ous effect on graft survival, rejection was associated
with polymorphonuclear cell infiltrates, conceivably re-
cruited into the graft by the soluble form of FasL (Kang3 Correspondence: haval.shirwan@louisville.edu
4 These authors contributed equally to this study. et al., 1997; Takeuchi et al., 1999). Additional factors,
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such as the expression level of FasL, the kinetics of and detected with both anti-FasL and anti-streptavidin
antibodies (Figure 1D). These results demonstrate thatexpression, the nature of microenvironment where FasL
is expressed, and the lack of mechanisms in selected the modified streptavidin in the chimeric protein has the
functional properties of native streptavidin with respecttissues that control the activity of FasL, may further
contribute to the opposing effects of FasL on the im- to binding to biotin and forming tetramers.
mune responses.
The apoptotic activity of FasL is most efficiently medi- Modification of the Cell Membrane for Rapid
ated by its trimerization and through cell-to-cell contact, and Durable Display of SA-FasL without
which is counterbalanced by the antiapoptotic activity Detectable Cellular Toxicity
of the soluble form (Suda et al., 1997; Schneider et al., The approach of cell membrane modification to display
1998). Therefore, the immunotherapeutic utility of FasL exogenous proteins chimeric with SA and its effective
may greatly benefit from the use of a modified form use for immunomodulation depend upon not only bio-
that possesses potent apoptotic function with minimal tinylation of the cell membrane without impairing the
chemotactic activity for polymorphonuclear cells, and cell viability and function, but also long-term persistence
its controlled expression on cells and tissues of interest. of biotin on the cell surface. To test whether our method
We, therefore, reasoned that fusion of the extracellular met these requirements, rat and mouse splenocytes
portion of FasL, lacking the metalloproteinase cleavage were biotinylated with various concentrations of a biotin
site, to the tetramer-forming domains of streptavidin derivative, Sulfo-NHS-LC-Biotin, and analyzed using
would produce a molecule possessing enhanced apo- flow cytometry. There was dose-dependent display of
ptotic activity and that the long-term transient display biotin on the cell surface, reaching a plateau at 5 M
of this protein on primary cells may allow for its effective (Figure 2A).
use for immunomodulation. Here, we demonstrate that To determine the kinetics of biotin persistence on
primary cells can be biotinylated and decorated with SA- resting and actively dividing cells, biotinylated spleno-
FasL under physiological conditions without detectable cytes were cultured with or without ConA for various
cellular toxicity. Biotin and SA-FasL persisted for weeks time points and analyzed by flow cytometry using strep-
on the cell surface in vitro and in vivo. Immunomodula- tavidin-APC. The kinetics of biotin display on the cell
tion with allogeneic splenocytes decorated with SA-FasL surface were monophasic with t1/2 of 18 and20 days for
effectively blocked primary and secondary alloreactive actively dividing and resting splenocytes, respectively
responses. Importantly, cotransplantation of islets with (Figure 2B). The faster kinetics of biotin turnover from
SA-FasL-decorated splenocytes into allogeneic host re- the surface of activated cells may be due to active cell
sulted in survival of the majority of grafts. Our data dem- division, leading to dilution of biotin on the cell surface,
onstrate that the cell membrane can be modified with faster turnover, or shedding of membrane proteins. The
biotin for rapid and long-term display of exogenous FasL long-term persistence of biotin on the cell surface was
chimeric with streptavidin in a functional form without not cell type specific since rat aortic endothelial cells
detectable cellular toxicity and that such decorated cells also retained biotin on the surface for extended periods
can effectively be used for immunomodulation. This of time (data not shown).
novel method of cell membrane modification for rapid To test whether biotin shows similar kinetics of cell
and long-term display of exogenous proteins provides surface persistence in vivo, rat splenocytes were biotin-
an alternative for gene transfer approaches with broad ylated, labeled with CFSE, and injected i.v. into synge-
research and therapeutic implications. neic animals. Spleens and lymph nodes (LNs) were har-
vested at various times postinjection and analyzed for
the presence of biotin on the surface of CFSE-positiveResults
lymphocytes using streptavidin-APC in flow cytometry.
The recovery of CFSE-positive cells per total cells in-Generation and Characterization of a Chimeric
SA-FasL Protein jected varied from 5% on day 1 to 0.5% on day 15
postinjection, irrespective of the cell membrane modifi-To test the feasibility of displaying exogenous proteins
chimeric with streptavidin on the surface of biotinylated cation with biotin. The kinetics of biotin loss from the
surface of cells migrated to the spleen were rather slow,cells, a chimeric gene consisting of the biotin binding
and tetramer-forming domains of streptavidin and extra- with over 90% and 45%–65% of the CFSE-positive cells
retaining biotin 10 and 15 days postinjection, respec-cellular portions of rat FasL was constructed using gene-
specific primers in PCR (Figure 1). Chimeric protein tively (Figure 2C). These data imply that biotin may per-
sist on the cell surface for weeks, if not for month(s).formed tetramers and oligomers under native polyacryl-
amide gel electrophoresis conditions that could only be We next tested the persistence of SA-FasL on the cell
surface. Splenocytes retained SA-FasL on their surfacedissociated into monomers under denaturing conditions
and by heating at 100C but not at 60C (Figures 1B and in vitro for more than 10 days of the culture period.
The kinetics of SA-FasL loss on the cell surface were1C). These structural features of SA-FasL are consistent
with those of native streptavidin, which forms stable biphasic with a slow initial phase followed by a rapid
phase with t1/2 of 8.5 days (Figure 2D). In contrast, thetetramers at 60C that can only be dissociated into mo-
nomers at 100C (Pahler et al., 1987; Green, 1990). To in vivo kinetics were monophasic with a t1/2 of3.5 days
(Figure 2E). The rapid turnover kinetics of SA-FasL intest whether streptavidin in the chimeric protein retains
its biotin binding capacity, culture supernatants were vivo as compared with in vitro may be due to capping
and modulation of SA-FasL from the cell surface, aug-analyzed using biotin-coated plates in a capture ELISA.
SA-FasL was effectively captured on biotinylated plates mented proteolytic cleavage, selected trapping of SA-
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Figure 1. Construction and Expression of
SA-FasL
(A) DNA encoding the core of streptavidin (SA)
was cloned from S. avidinii using specific
primers (a, b) in PCR. A cDNA encoding the
extracellular domains of rat FasL without the
metalloproteinase cleavage site was cloned
using primers c and d in RT-PCR. Both genes
were subcloned into the PMT/BiP/V5-HisA
CuSO4-inducible expression vector (Invitro-
gen). A 6xHis tag was engineered into the
genes to facilitate protein purification using
metal affinity columns.
(B and C) Western blot analysis of chimeric
SA-FasL. Culture supernatants from S2 trans-
fectants were analyzed using Western blots
under native (B) and denaturing (C) condi-
tions. SA-FasL was detected using rabbit
anti-rat FasL serum as primary and HRP-con-
jugated goat anti-rabbit as secondary re-
agents. Bands at 33, 66, 132, and approxi-
mately 250 kDa represent monomers, dimers,
tetramers, and higher-order structures, re-
spectively, formed by the SA moiety of the
chimeric protein.
(D) Detection of SA-FasL with capture ELISA.
SA-FasL in culture supernatant was captured
on biotin-coated plates and detected using
anti-FasL and anti-streptavidin antibodies.
Supernatant from S2 cells transfected with
the expression vector containing FasL cDNA
with a 5 frame-shift mutation served as nega-
tive control.
FasL-displaying cells in anatomical compartments other with 5% death observed in cultures incubated with
core streptavidin (SA) or a human CD40L chimeric withthan the spleen and LNs, specific clearance of these
SA (SA-CD40L; Figure 3A). Human CD40L does notcells, or other unidentified factors. CFSE-positive cells
crossreact with mouse or rat CD40 receptor (N.P.S. etextracted from LNs showed similar kinetics of SA-FasL
al., unpublished data, and Baccam and Bishop, 1999)turnover to the cells isolated from spleens (data not
and as such serves as a negative control for SA-FasL.shown).
SA-FasL also showed potent apoptotic activity when
displayed on the cell membrane. Coculture of SA-FasL-
Induction of Apoptosis in Fas Cell Lines and Activated decorated splenocytes (100 ng/106 cells) at a one-to-
Lymphocytes Using SA-FasL as Soluble Protein one ratio with Jurkat or A-20 cells resulted in significant
or Displayed on the Cell Membrane cell death, varying between 66% and 90% depending
The modification of cell membrane with biotin for rapid on culture conditions and cell type used (Figure 3B).
display of exogenous chimeric proteins as an alternative The observed cell death was due to apoptosis since a
to gene transfer approaches for immunomodulation may significant portion of procaspase-3 was converted into
not only depend upon long-term display of proteins on the activated form, and this activation correlated with
the cell surface but also on their anticipated functions. DNA fragmentation and cleavage of caspase-3 sub-
To test whether FasL in the chimeric molecule preserves strate poly(ADP-ribose) polymerase (PARP; Figures 3C
its apoptotic function, Fas human Jurkat and mouse and 3D). Taken together, these data demonstrate that
A20 lymphoma cell lines were used as targets. Overnight FasL in the chimeric molecule preserves its apoptotic
incubation with the soluble SA-FasL protein (100 ng/ function as a soluble protein or when displayed on the
surface of another cell.106 cells) resulted in95% total cell death as compared
Immunity
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Figure 2. Persistent Long-Term Display of Biotin and SA-FasL on the Cell Surface
(A) Rat splenocytes were biotinylated with the indicated concentrations of EZ-Link biotin and stained with streptavidin-APC for analysis in
flow cytometry.
(B) Biotinylated (15 M) splenocytes were cultured in the absence (No ConA) or presence of 2.5 g/ml ConA (ConA) and harvested at various
days postactivation to determine the level of biotin on the cell surface using streptavidin-APC in flow cytometry (MFI for unstimulated and
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Figure 3. SA-FasL Induces Apoptosis in Fas Cells
(A) Apoptosis in mouse A20 cell line. A20 cells were incubated with SA-FasL (100 ng/106 cells) overnight, and apoptosis was determined using
propidium iodide (PI) and Annexin V-FITC in flow cytometry. Cells incubated in S2 control supernatant, core streptavidin (SA), or human SA-
CD40L chimeric protein (CD40L) served as negative controls.
(B) Induction of apoptosis using splenocytes decorated with SA-FasL. Jurkat cells were incubated with SA-FasL-decorated rat splenocytes
at various ratios overnight, and apoptosis was assessed using PI and Annexin V-FITC in flow cytometry. Anti-human CD3-APC was used to
gate on Jurkat cells. Data are representative of at least four independent experiments.
(C and D) Apoptosis in Jurkat cells incubated with the soluble SA-FasL under similar conditions as described for A20 cells was further assessed
by genomic DNA analysis using agarose gels (C) and Western blots using antibodies against caspase-3 and its substrate PARP (D).
Inhibition of Primary and Secondary Alloreactive for immunomodulation using conventional gene transfer
approaches (Griffith et al., 1995; Lau et al., 1996; MatsueResponses Using Splenocytes Decorated
with SA-FasL for Immunomodulation et al., 1999). We therefore investigated whether spleno-
cytes decorated with SA-FasL can inhibit alloreactiveFasL-mediated apoptosis is critical to AICD that regu-
lates immune homeostasis (Wu et al., 1994; Parijs et al., lymphocytes when used as APCs. ACI splenocytes were
biotinylated (5 M), decorated with SA, human SA-1996). This aspect of FasL has widely been exploited
ConA-stimulated cultures on day 1 were 932 	 250 and 850 	 200 and on day 20 were 45 	 10 and 30 	 8, respectively).
(C) Kinetics of cell-surface biotin loss in vivo. Rat splenocytes were biotinylated (15 M), labeled with CFSE, and injected i.v. into syngeneic
rats. Splenocytes harvested at different times were analyzed for the presence of biotin on CFSE-gated cells using streptavidin-APC in flow
cytometry. Data in (A), (B), and (C) are representative of three to six independent experiments.
(D and E) Rat splenocytes were biotinylated (15 M) and decorated with SA-FasL (50–100 ng/106 cells). Cells were then either kept in tissue
culture (D) or labeled with CFSE and injected i.v. into syngeneic animals (E). Cells were harvested at the indicated times and the display of
SA-FasL on the cell surface was determined using an APC-labeled anti-FasL antibody (MFL4) in flow cytometry (gated on CFSE-positive cells
for in vivo experiments).
Immunity
800
Figure 4. Splenocytes Displaying SA-FasL Block Primary and Secondary Alloreactive Responses In Vitro
(A) The presence of SA, human SA-CD40L, and SA-FasL on ACI splenocytes. SA-FasL, human SA-CD40L, and SA on the cell surface were
detected using monoclonal antibodies labeled with APC against rat FasL, human CD40L, and a competition assay between unlabeled core
streptavidin and APC-labeled commercial streptavidin, respectively.
(B) PVG.1U LN cells (1
 105) were cocultured with irradiated ACI splenocytes (None), biotinylated splenocytes decorated with core streptavidin
(SA), human SA-CD40L (CD40L), or SA-FasL (FasL) for 5 days. Data shown are from one of several representative experiments.
(C) PVG.1U splenocytes were stimulated with irradiated ACI splenocytes for 5 days. T cells were purified by Ficoll gradient and used as
responders to irradiated ACI splenocytes decorated with FasL in a 3 day MLR culture (Allo-FasL). Biotinylated ACI splenocytes treated with
S2 supernatant (Allo-S2) and unmodified ACI splenocytes (Allo) served as controls. Irradiated PVG.1U splenocytes were used as targets for
syngeneic response (Syn). Data are the mean 	 SD of triplicate cultures.
(D) Splenocytes displaying FasL induce apoptosis in activated T cells. PVG.1U cells were activated with ConA for 3 days to upregulate Fas
and used as target for FasL-displaying irradiated ACI splenocytes at 1:1 effector:target ratios. Apoptosis was determined by flow cytometry
using PE-labeled Annexin V and 7-AAD after 16 hr of incubation. Analyses were performed by gating on PVG.1U cells (positive for a monoclonal
Ab against rat class I Au labeled with FITC). Unmodified ACI splenocytes (Control) and biotinylated ACI splenocytes decorated with S2 culture
supernatant (S2), SA, or human SA-CD40L proteins served as negative controls.
CD40L, or SA-FasL (50–100 ng/106 cells; Figure 4A), and 0.005; Figure 4B). Alloinhibition was SA-FasL specific,
since biotinylated splenocytes displaying similar levelsused to stimulate allogeneic LN cells in a standard mixed
lymphocyte reaction (MLR) assay (Shirwan et al., 1997). of SA or SA-CD40L had no inhibitory effect.
To test whether SA-FasL-displaying splenocytes blockFasL-displaying cells almost completely (98%) blocked
the proliferative response induced by alloantigens (p  the proliferative response of antigen-experienced lym-
Immunomodulation with FasL-Decorated Cells
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phocytes, PVG.1U LN cells were first stimulated with on antigen presentation. Once effectively activated by
unmanipulated splenocytes, alloreactive T cells wereirradiated ACI splenocytes for 5 days in culture. Acti-
vated lymphocytes were harvested by Ficoll gradient expected to undergo apoptosis by their specific and/or
nonspecific interaction with SA-FasL-decorated spleno-and restimulated with SA-FasL-decorated ACI spleno-
cytes in a 3 day MLR assay. There was greater than cytes in the same microenvironment. In unmanipulated
controls (n  13), allogeneic islets were rejected with a87% inhibition of the alloreactive response, which was
statistically significant (p  0.005; Figure 4C). Biotinyl- mean survival time (MST) of 9 	 1.6 days (Figure 6A).
Cotransplantation of donor biotinylated splenocytesated splenocytes treated with S2 control supernatant
moderately inhibited the alloreactive response. treated with S2 supernatant led to slightly (p  0.441)
accelerated rejection (MST  8 	 3.3 days; n  9).To provide evidence that SA-FasL-induced apoptosis
of lymphocytes is the primary mechanism responsible Splenocytes decorated with SA-FasL prolonged the sur-
vival of all allogeneic islets (n  10) beyond the 9 dayfor alloinhibition, PVG.1U splenocytes were stimulated
with ConA to upregulate Fas and used as targets for MST for the unmanipulated controls (p  0.001). The
majority of islet allografts (6/10) were not rejected duringallogeneic ACI splenocytes decorated with SA, human
SA-CD40L, or SA-FasL (Figure 4A). Coculture of target the 56 day observation period (Figure 6B). Importantly,
the euglycemia observed in long-term recipients wascells with SA-FasL-decorated allogeneic effectors at a
1:1 ratio for 18 hr resulted in 95% total cell death due to allogeneic islets since nephrectomy of the kidney
harboring these islets 8 weeks after transplantation re-(Figure 4D). In contrast, there was23% total cell death
in cultures containing allogeneic stimulators decorated sulted in hyperglycemia in all animals (n 5; Figure 6C).
Treatment of rodents with antibodies against Fas orwith control S2 supernatant, SA, or human SA-CD40L,
which was similar to the total cell death in cultures coin- FasL protein has been reported to cause liver toxicity
in selected systems (Schneider et al., 1998). To assesscubated with unmodified ACI splenocytes.
The impressive alloinhibition observed in vitro led us hepatotoxicity in our model, rats were injected i.v. with
high doses of SA-FasL-decorated cells (0.5–1 
 108to test whether SA-FasL-decorated splenocytes would
block primary and secondary alloreactive immune re- cells/rat). No detectable signs of acute or chronic liver
toxicity were seen, as evidenced by 100% survival of thesponses in vivo. PVG.1U rats were immunized i.p. with
1 
 107 irradiated and SA-FasL-decorated ACI spleno- animals (n 40), normal activity of serum transaminases
(Figures 7A and 7B), normal histology, and the lack ofcytes. Mesenteric LN cells or splenocytes were har-
vested on various days postimmunization and used as significant apoptosis (Figure 7C).
responders to donor and third party antigens in MLR
assays. Splenocytes decorated with SA-FasL effectively Discussion
blocked the alloreactive response to donor antigens in
naive animals (90%–95%, p  0.005; Figure 5A). This Expression of exogenous proteins with defined thera-
inhibition was FasL- and antigen specific since re- peutic functions using conventional gene transfer ap-
sponses to biotinylated splenocytes treated with S2 su- proaches holds great promise for the treatment of both
pernatant and third party LEW antigens were almost inherited and acquired diseases. Gene therapy has been
unaltered. The alloreactive response generated in immu- used extensively for immunomodulation either to induce
nized animals was significantly augmented (p  0.005) immune response to infectious agents and tumors (Bar-
as compared with that in naive animals, demonstrating ouch et al., 2000; Wierda et al., 2000) or to downregulate
efficient immunization. SA-FasL-decorated splenocytes the immune response to prevent or treat autoimmune
were also effective in blocking secondary alloreactive diseases or rejection of foreign grafts (Lau et al., 1996;
responses (95%) in antigen-sensitized animals (Fig- Zhang et al., 1997, 1999; Matsue et al., 1999). Although
ures 5B and 5C). Alloinhibition was systemic and antigen gene therapy has evolved in recent years toward becom-
specific since both splenocytes and LN cells of immu- ing a more clinically applicable approach, a series of
nized rats generated a response to third party but not difficulties remain to be overcome before its full potential
to donor antigens (Figure 5D). Alloinhibition was depen- is realized. Therefore, we reasoned that a method that
dent on the presence of a functional Fas molecule in the allows for rapid and long-term transient display of exog-
host since immunomodulation with SA-FasL-decorated enous proteins on the cell surface may have important
allogeneic splenocytes prevented alloreactive response therapeutic implications, particularly in the area of im-
in FasL-deficient gld but not Fas-deficient lpr mice (Fig- munomodulation, and hence may offer a viable alterna-
ure 5E). tive to gene transfer approaches.
Here, we report an effective method of cell membrane
modification to achieve long-term display of exogenousPrevention of Allogeneic Islet Rejection Using
Splenocytes Decorated with SA-FasL proteins. This method involves biotinylation of cells and
decoration with proteins chimeric with core streptavidinfor Immunomodulation
The robust inhibitory effect of SA-FasL-decorated under physiological conditions in less than 2 hr. Biotin
persisted on the cell surface for extended periods ofsplenocytes on alloreactive responses led us to test this
regimen for the prevention of islet allograft rejection. time in vitro (t1/2  20 days) and in vivo (t1/2  15 days).
Persistence of biotin on the cell surface for periods ofC57BL/10 islets were cotransplanted with a mixture of
irradiated, unmodified (3 
 106), and FasL-decorated month(s) indicates a slow rate of detachment and turn-
over of the biotinylated surface molecules or perhaps(1 
 106) splenocytes under the kidney capsule of dia-
betic BALB/c mice. Unmanipulated splenocytes were their internalization and reappearance on the cell sur-
face (Raub et al., 1986). These data suggest that theused to offset any negative effect biotinylation may have
Immunity
802
Figure 5. Splenocytes Displaying SA-FasL Block Primary and Secondary Alloreactive Responses In Vivo
(A) SA-FasL blocks primary alloreactive responses in vivo. PVG.1U rats were immunized i.p. with irradiated ACI splenocytes (Allo: 1 
 107
cells/animal), biotinylated cells treated with S2 supernatant (Allo-S2), or biotinylated cells decorated with SA-FasL (Allo-FasL). LNs were
harvested 6 days later and used as responders to irradiated splenocytes from PVG.1U (Syn; autoresponse), ACI (Allo), or LEW (Third party)
rats in a 3 day MLR assay. Data represent one of three independent experiments performed with a minimum of six rats per treatment regimen.
LNs from naive PVG.1U animals served as controls (None).
(B) SA-FasL-decorated splenocytes block alloreactive responses in sensitized rats. PVG.1U rats were first immunized i.p. with irradiated ACI
splenocytes and boosted 14 days later with the same number of unmanipulated (Allo), biotin  S2 supernatant (Allo-S2), or biotin  SA-FasL
(Allo-FasL) splenocytes. LNs were harvested 3 days later and used as responders to irradiated splenocytes from PVG.1U (Syn), ACI (Allo), or
LEW (Third party) rats in a 3 day MLR assay. LN cells from naive animals served as controls (None). Data represent one of three independent
experiments performed with a minimum of six rats per treatment regimen.
(C) Time course response of MLR. Cultures similar to those in (B) were harvested at the indicated periods of time to test whether there is
complete blockade of the alloreactive response.
(D) Inhibition of alloresponse induced by SA-FasL-decorated splenocytes is systemic. PVG.1U rats were immunized i.p. with irradiated ACI
splenocytes. The immunized animals were then boosted twice on days 14 and 17 after the first immunization with unmanipulated ACI
Immunomodulation with FasL-Decorated Cells
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Figure 6. Splenocytes Displaying SA-FasL Prevent Rejection of Allogeneic Islet Grafts
Pancreatic islets were isolated from C57BL/10 (H-2b) mice and cotransplanted (400–600) with a mixture of unmodified (3 
 106) and SA-FasL-
decorated splenocytes (1
 106) into streptozocin-induced diabetic BALB/c (H-2d) recipients. Rejection was assessed as complete when blood
glucose level was above 300 mg/dl for 3 consecutive days.
(A) Survival of allogeneic control islets (….), islets cotransplanted with S2-treated splenocytes (—), or islets cotransplanted with splenocytes
decorated with SA-FasL (__).
(B) Blood glucose levels in diabetic BALB/c animals cotransplanted with C57BL/10 islets and SA-FasL-decorated splenocytes.
(C) Excision of allogeneic islets (Ex) in long-term graft survivors by nephrectomy 56 days after transplantation resulted in hyperglycemia,
demonstrating the survival and function of transplanted islets.
turnover kinetics of some cell membrane proteins may of cells and the detection techniques used to determine
turnover rates. The flow cytometry used in our studybe much slower than previously described (Raub et al.,
1986; Hare and Taylor, 1991; Hare and Holocher, 1994). allows for real-time detection of cell membrane proteins
and is also a much more sensitive and quantitative assaySeveral studies reported t1/2 for the turnover of mamma-
lian cell-surface proteins to be in the range of 16 to 100 as compared with the conventional protein labeling and
gel electrophoresis methods used in previously pub-hr (Raub et al., 1986; Hare and Taylor, 1991; Hare and
Holocher, 1994). The discrepancy between our data and lished studies.
The long-term persistence of biotin on the cell surfacethe results of previous studies may be due to the types
splenocytes (Allo), biotinylated splenocytes S2 supernatant (Allo-S2), or biotinylated splenocytes SA-FasL (Allo-FasL). LNs and splenocytes
were harvested from immunized animals and used as responders to irradiated splenocytes from ACI in a 3 day MLR assay. Data represent
one of three independent experiments performed with a minimum of six rats per treatment regimen.
(E) Alloinhibition is associated with Fas/FasL interaction. Lpr and gld mice were immunized i.p. with 5 
 106 B10.BR irradiated splenocytes
decorated with SA-FasL. LNs were harvested 6 days after immunization and used as responders to syngeneic (Syn), B10.BR (Allo), and BALB/
c (third party) splenocytes in MLR. Data shown are the mean 	 SD of triplicate cultures and representative of three independent experiments.
Immunity
804
Figure 7. SA-FasL-Decorated Cells Do Not Cause Liver Toxicity
(A and B) Serum aminotransferase activity. Rats were injected intravenously with 0.5–1 
 108 unmanipulated cells (Control) and biotinylated
cells decorated with SA-FasL (FasL) or treated with S2 control supernatant (S2). Sera were harvested at various time periods after injection
and analyzed for the activity of serum aspartate aminotransferase (A) or alanine aminotransferase (B). Data represent mean 	 SEM for two
to three animals per group for S2 and controls and three to five animals per group for SA-FasL.
(C) Liver histology of control and experimental animals. Livers from animals injected with control cells (Control) and SA-FasL-decorated cells
(FasL) were harvested at various times postinjection (histology shown here is for 3 day samples) and analyzed by hematoxylin-eosin (upper
panels) and TUNEL staining (lower panels). A minimum of 2500 cells/histology were examined for TUNEL-positive cells (apoptotic) using a
computer with SigmaScan (arrows show apoptotic cells). There was no detectable toxicity in livers harvested from FasL-treated animals by
TUNEL or histological analysis. Apoptotic tissues provided with the TUNEL kit were used as positive controls (TUNEL control).
provides a platform for extended display of exogenous protein consisting of human CD80 and streptavidin
showed slower in vivo kinetics of turnover with a t1/2proteins chimeric with streptavidin/avidin. In confirma-
tion of this notion, SA-FasL was efficiently displayed on of 10 days (N.P.S. et al., submitted). Biotinylation and
decoration with SA-FasL were not toxic to the cells northe cell surface in a functional form. Unlike biotin, which
persisted on the cell surface with a t1/2 of 15 days, SA- did they significantly interfere with antigen presentation
function of the cells. Furthermore, transplantation ofFasL showed faster kinetics of turnover in vivo with t1/2
of 3.5 days. This may plausibly be due to the proteo- bone marrow cells decorated with SA-FasL into lethally
irradiated allogeneic rats resulted in efficient engraftmentlytic cleavage or modulation of SA-FasL from the cell
surface or other undefined factors. The kinetics of cell and rescue of these animals from death (E.S.Y., unpub-
lished data). The presence of multilineage donor chime-surface persistence were protein dependent. A chimeric
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rism in these animals further suggested that biotinylation think that the form of FasL and its mode of expression
used in this study may provide an explanation. SA-FasLand decoration with SA-FasL were not toxic to the stem
cells nor did they interfere with the homing of stem cells lacks the metalloproteinase cleavage site necessary for
generation of the soluble form from the wild-type mole-to the bone marrow, proliferation, and differentiation
into various hematopoietic lineages. cule expressed on the cell surface (Tanaka et al., 1998).
In addition, SA-FasL exists as tetramers or higher-orderThis study demonstrates weeks-long persistence of
exogenous proteins on the cell membrane in vivo. Sev- structures with potent apoptotic activity as compared
with soluble FasL. The potent apoptotic activity of theeral different approaches have previously been used to
modify the cell membrane for the display of exogenous SA-FasL used in our system, combined with display of
this molecule on the cell surface at high levels, may leadproteins in vitro (Zhang et al., 1992; Wahlsten et al.,
1998; Chen et al., 2000). These approaches include (1) to the elimination of virtually all Fas cells with which
SA-FasL-bearing cells come into close contact. This mayanchorage of proteins with a glycosyl phosphatidylinosi-
tol moiety to the cell membrane (Zhang et al., 1992), (2) allow for efficient elimination of inflammatory infiltrates,
thereby providing long-term survival of transplanted is-derivatization of proteins with palmitic acid and insertion
of the derivatized proteins into the cell membrane (Chen lets. In contrast, ectopic expression of wild-type FasL
on a continuous basis may result in the accumulationet al., 2000), (3) derivatization of the cell membrane with
iminodiacetic acid and nitrolotriacetic acid for anchor- of the soluble form of FasL in the graft. The soluble form
may then recruit inflammatory infiltrates into the graftage of His-tag-containing proteins (van Broekhoven et
al., 2000), and (4) insertion into the cell membrane of and serve as an antiapoptotic factor, reducing the apo-
ptotic effect of the membrane-bound form and leadingproteins with hydrophobic tails (Wahlsten et al., 1998).
All these approaches were efficient for the short-term to the destruction of islets. This contention is consistent
with observations that the membrane-bound form of(1–3 days) display of proteins in vitro. Their failure to
cause longer-term persistence may be due to the weak FasL is apoptotic and does not mediate chemotaxis of
neutrophils, whereas the soluble form not only servesnature of chemical interactions involved in anchorage
of proteins to the cell membrane in these systems. It is as a chemotactic factor for neutrophils, but may also
prevent apoptosis by competing with the membrane-also unknown if these approaches will prove effective
in vivo. bound form for binding to Fas (Suda et al., 1997; Schnei-
der et al., 1998; Seino et al., 1998; Ottonello et al., 1999).Another important feature of proteins chimeric with
streptavidin/avidin is their ability to exist as tetramers Although our data imply the physical deletion of allore-
active lymphocytes by Fas/FasL-mediated apoptosis toand even higher-order structures due to the inherent
physical-chemical properties of streptavidin/avidin (Pahler be responsible for the observed alloinhibiton, we cannot
eliminate the possibility of other immunoregulatoryet al., 1987). Inasmuch as coaggregation of receptor/
ligand interactions can be critical to effective signal mechanisms in play in vivo. Apoptotic lymphocytes have
been shown to shift immune responses from a Th1 in-transduction (Grakoui et al., 1999), our technology not
only allows for display of exogenous proteins on the cell flammatory to a Th2 anti-inflammatory response via their
elaboration of IL-10 and TGF- (Chen et al., 2001). Fur-surface but may also augment their function. Consistent
with this notion are our preliminary observations that thermore, a recent study demonstrated the presence of
liver-specific immunoregulatory cells whose emergencethe SA-FasL molecule possesses robust apoptotic ac-
tivity as compared with soluble FasL (data not shown). depended on Fas/FasL interaction (Watanabe et al.,
2002). Therefore, additional studies are needed to delin-Furthermore, immunization of rats with allogeneic splen-
ocytes decorated with SA-FasL efficiently blocked allo- eate the precise mechanisms of alloinhibition observed
in our model.reactive responses not only in naive but also in sensi-
tized animals. The inhibitory response was antigen The present report demonstrates that cells can be
modified with biotin to achieve transient long-term cell-specific, systemic, and mediated through Fas/FasL in-
teraction since mice lacking the Fas receptor were not surface display of functional proteins chimeric with core
streptavidin. The procedure is performed in a short pe-sensitive to alloinhibition. The inhibition of alloreactive
responses in sensitized animals is significant since most riod of time (2 hr) without detectable cellular toxicity.
The amount of chimeric protein on the cell surface isof the studies using conventional gene transfer ap-
proaches for the ectopic expression of FasL on macro- easily adjusted by varying the concentration of biotin.
Use of this method results in the immediate presencephages and dendritic cells have demonstrated the utility
of these cells in the inhibition of only primary alloreactive of a functional protein on the cell surface without the
time lag required for gene transfer-based expression.responses (Matsue et al., 1999).
Cotransplantation of splenocytes decorated with SA- Several proteins may be displayed simultaneously on
the cell surface with comparable kinetics, maximizingFasL with syngeneic islets into diabetic allogeneic hosts
resulted in the prevention of islet rejection and the resto- their therapeutic effectiveness. Cells displaying several
of these molecules may also be used as vehicles forration of glucose homeostasis in the majority of graft
recipients. This is consistent with the studies of Lau et targeted delivery of proteins in vivo (E.S.Y., unpublished
data). Hence, this approach may offer increased efficacyal. (1996) reporting excellent survival of islet allografts
cotransplanted with syngeneic myoblasts genetically and safety as compared not only with conventional gene
therapy but also with systemic delivery of purified pro-engineered to express FasL. However, our data differ
from the observations that transgenic expression of teins for the treatment of selected disorders. Rapid and
durable cell-surface display of functional proteins offersFasL in cells of islets does not confer immune privilege,
but rather targets the cells for rapid destruction in alloge- a novel means of intervention in the areas of autoimmu-
nity, transplantation, and vaccines. This approach pos-neic hosts (Allison et al., 1997; Kang et al., 1997). We
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For in vivo experiments, splenocytes were biotinylated, labeledsesses the simplicity, safety, and efficacy required to
with CFSE (2.5 M; Molecular Probes, Eugene, OR), and decoratedmake it a clinically relevant alternative that may accom-
with SA-FasL. Thirty to sixty million of these cells were injected i.v.plish the same end as gene therapy in the treatment of
into syngeneic animals. Spleens and LNs were harvested at various
a broad spectrum of immune-based disorders. times postinjection and analyzed for the presence of biotin and SA-
FasL on the surface of CFSE-positive cells using flow cytometry.
Experimental Procedures Controls included cells, cells labeled with CFSE, and cells labeled
with CFSE and modified with biotin.
Animals
BALB/c (H-2d), C57BL/10 (H-2b), B10.BR (H-2k), C57BL6.gld (H-2b),
Apoptosis Assaysand C75BL/6.lpr (H-2b) mice were purchased from Jackson Labora-
Human Jurkat or mouse A20 cells (1 
 106/ml) were incubated intory (Bar Harbor, ME). PVG.1U (RT1u) and PVG.R8 (RT1.AaBuDuCu)
the presence of 100 ng of SA, human SA-CD40L, or SA-FasL forrats were bred in our animal colony at the University of Louisville.
4–24 hr at 37C in a 5% CO2 incubator. Similarly, FasL-decoratedACI (RT1a) and LEW (RT1l) rats were obtained from Harlan Sprague
splenocytes were coincubated with ConA-activated lymphocytes,Dawley (Indianapolis, IN). Care and maintenance of animals were in
Jurkat, or A20 cells at 0.1–5 effector:target ratios for 4–24 hr. Cellsaccordance with Institutional and NIH guidelines.
were stained with propidium iodide or 7-amino actinomycin D (7-AAD)
as markers for dead cells and Annexin V labeled with appropriateConstruction of SA-FasL and Expression in Drosophila S2 Cells
fluorochromes as markers for apoptotic cells. To determine apopto-Genomic DNA was isolated from Streptomyces avidinii (ATCC), and
sis in target cells, these cells were stained with fluorochrome-conju-0.2 g of this DNA was used as template for amplification using
gated antibodies against a cell-specific marker (anti-human CD3primers specific for core streptavidin in PCR (Pahler et al., 1987).
antibody for Jurkat and anti-mouse B220 for A20 cells).The 5-primer included sequences for BglII and 6 His residues to
Apoptosis was further confirmed by analysis of activation of cas-allow cloning in frame with the Drosophila secretion signal (BiP) for
pases using Western blots. Total cellular proteins were extractedexpression as a secreted protein and purification using Ni-affinity
with lysis buffer (150 mM NaCl, 50 mM Tris-Cl [pH 8.0], 1% NP40,columns. The extracellular domain of rat FasL without the metallo-
and 1 mM EDTA) in the presence of a cocktail of proteinase inhibi-proteinase site was cloned using a FasL cDNA clone isolated from
tors. Equal amounts of proteins were fractionated in 10% SDS-ConA-activated splenocytes as a template and a sense primer to
PAGE gels and transferred to a nitrocellulose membrane. Westernthe 5-end of the extracellular region, FasL6 (nucleotides 428–453)
blot analysis was performed using antibodies against PARP (Rabbitcontaining an EcoRI site, and an antisense primer to the 3-end
polyclonal anti PARP, Roche) and a cocktail of two anti caspase-3untranslated region of FasL, FasL2 (nucleotides 977–998) containing
Abs that recognize both pro- and active forms of caspase-3 (Rabbitan EcoRI site in frame with SA, in PCR. The chimeric gene was
polyclonal anti caspase-3, H-277, Santa Cruz, CA, and anti CPP 32subcloned into pMT/BiP/V5-His CuSO4-inducible vector for expres-
YAMA, PharMingen, CA). Visualization of proteins was performedsion in the DES system (Invitrogen; Figure 1A). Supernatant collected
with HRP-conjugated secondary antibodies. A DNA ladder assay1–4 days after induction of S2 transfectants was either used immedi-
was also performed to confirm apoptosis.ately or precipitated with 50% ammonium persulfate, dialyzed
against PBS, and purified using Ni-NTA columns (QIAGEN, Valencia,
CA). The concentration of purified or culture supernatant SA-FasL Immunomodulation with FasL-Decorated Allogeneic Splenocytes
was determined by the Bradford method or ELISA, respectively, Rats were immunized i.p. or i.v. with irradiated (2000 cGy) allogeneic
using known amounts of commercially available streptavidin as splenocytes (1
 107) decorated with SA-FasL. Unmanipulated cells
standard. and cells modified with biotin and decorated with control S2 super-
natant, SA, and human SA-CD40L were used as controls. Animals
Characterization of SA-FasL by Western Blot and ELISA were then boosted with different forms of allogeneic cells at various
The expression of SA-FasL was first detected using biotin-coated days after the first immunization. Mesenteric LN cells or splenocytes
microwell strip plates and the anti-FasL MFL4 mAb in ELISA (Pierce, were harvested 3 or 6 days after the last immunization and used as
Rockford, IL). For Western blot analysis, culture supernatants were responders to donor and third party antigens in MLR cultures (Shir-
fractionated by PAGE under native and denaturing conditions and wan et al., 1997).
transferred onto PVDF membranes using a semidry-blot apparatus
(BioRad). Membranes were incubated with blocking buffer (5% dry
In Vitro Proliferation Assaysmilk and 0.5% Tween 20 in PBS), followed by incubation with rabbit
LN cells or splenocytes were harvested from naive or manipulatedanti-rat FasL serum (C-178; Santa Cruz, CA) at 1:1000 dilution in
animals and used in in vitro proliferation assays (Shirwan et al.,the blocking buffer for 1 hr at room temperature. Membranes were
1997). Responder and stimulator cells were cocultured in triplicatethen washed extensively and incubated with HRP-conjugated goat
at a cell concentration of 1 
 105 cells/well in 200 l of completeanti-rabbit antibody at 1:5000 dilution for 1 hr, and proteins were
MLR medium in 96-well U-bottom microtiter plates (Corning Glassdetected using a chemiluminescent substrate (Molecular Dynamics,
Works, Corning, NY) for 3–5 days and pulsed with 1 Ci of [3H]thymi-San Diego, CA).
dine (NEN Life Sciences Products, Boston, MA) for the last 18 hr of
the culture period. All MLR assays were performed in three replicateModification of the Cell Membrane with Biotin
wells per data point, and results are presented as mean 	 SD ofand Decoration with SA-FasL
triplicate wells of representative experiments. Responses to synge-Various cell types were incubated in 1.5–150 M freshly prepared
neic and third party antigens served as controls.EZ-Link Sulfo-NHS-LC-Biotin (Pierce) in PBS for 30 min at room
temperature. Cells were washed twice and resuspended in PBS
supplemented with 50–100 ng of SA-FasL per 106 cells. After incuba- Islet Transplantation
Diabetes was induced in BALB/c recipients by i.p. injection of strep-tion at 4C for 20–30 min with intermittent mixing, cells were washed
twice and analyzed in flow cytometry using streptavidin-APC and tozocin (260 mg/kg). Pancreatic islets were prepared according to a
standard protocol (Steiger et al., 1995). Splenocytes were harvestedMFL4 labeled with different fluorochromes to assess the cell-surface
levels of biotin and SA-FasL, respectively. from C57BL/10, biotinylated (15 M), decorated with FasL (50–100
ng/106 cells) or control S2 supernatant, and irradiated (2000 rads).
A mixture of unmodified (3 
 106) and FasL-decorated splenocytesKinetics of Biotin and SA-FasL Display on the Cell Surface
Splenocytes or rat aortic endothelial cells were biotinylated (15 M) (1 
 106) was cotransplanted with 400–600 islets under the kidney
capsule of diabetic BALB/c mice. Survival of islets was assessed byand decorated with SA-FasL (50–100 ng/106 cells) and maintained
in cultures with or without ConA for various times. The presence of monitoring blood glucose levels starting 3 days after transplantation.
Kidneys receiving the transplanted islets and splenocytes were sur-cell surface biotin and SA-FasL was detected by flow cytometry
using streptavidin-APC and MFL4 mAb labeled with various fluoro- gically removed 56 days after transplantation to test whether eugly-
cemia established in transplanted animals was due to the trans-chromes, respectively. Unmodifed cells served as negative controls.
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planted islet allografts rather than the recovery of function by the molecular machine controlling T cell activation. Science 285,
221–227.host islets.
Green, N.M. (1990). Avidin and streptavidin. Methods Enzymol. 184,
Histological Analysis and TUNEL Assay 51–67.
Livers were harvested from animals injected with cells decorated Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., and Ferguson,
with SA-FasL or unmanipulated cells various times postinjection, T.A. (1995). Fas ligand-induced apoptosis as a mechanism of im-
and tissues were processed for hematoxylin-eosin (H & E) staining mune privilege. Science 270, 1189–1192.
and TUNEL assay. An ApopTag in situ detection kit was used to
Hare, J.F., and Holocher, A. (1994). Solubility in non-ionic detergentsdetect fragmented nuclei in liver tissues according to the manufac-
distinguishes between slowly and rapidly degraded plasma mem-turer’s instructions (INTERGEN Company, Purchase, NY).
brane proteins. J. Biol. Chem. 269, 5981–5988.
Hare, J.F., and Taylor, K. (1991). Mechanisms of plasma membraneStatistical Analysis
protein degradation: recycling proteins are degraded more rapidlyResults are expressed as means	SD. Comparison between groups
than those confined to the cell surface. Proc. Natl. Acad. Sci. USAwas done using ANOVA. Control groups were compared to experi-
88, 5902–5906.mental groups in order to determine whether the differences in vari-
Kang, S.M., Schneider, D.B., Lin, Z., Hanahan, D., Dichek, D.A.,ances were statistically significant. ANOVA single factor analyses
Stock, P.G., and Baekkeskov, S. (1997). Fas ligand expression inwere performed with background controls. In addition, the means
islets of Langerhans does not confer immune privilege and insteadfor each group were compared with the control groups using the
targets them for rapid destruction. Nat. Med. 3, 738–743.Two Sample for Means test and assuming means differences to be
zero. Results were considered statistically significant if the ANOVA Lau, H.T., Yu, M., Fontana, A., and Stoeckert, C.J., Jr. (1996). Preven-
p value was below 0.05. Graft survival data were compared by tion of islet allograft rejection with engineered myoblasts expressing
Kaplan-Meier/Mann-Whitney U tests. FasL in mice. Science 273, 109–112.
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